Current Funding:
NIH/NCI: 1K08CA248962-01 - 4/1/2020-3/30/2025
Gamma delta T-cell immunotherapy for T-cell acute lymphoblastic leukemia.
Goal: to target T-ALL with innate-like cytotoxic gamma delta (γδ) T cells using two different strategies, one utilizing cellular stress modulation to sensitize T-ALL to γδ T-cell killing, and the other through the use of CD5-directed chimeric antigen receptors (CARs).
Role: PI
Pediatric Research Alliance Center for Drug Discovery Pilot Award - 10/1/2022-9/30/2024
Utilizing ancestral sequence reconstruction to develop a novel L-asparaginase with reduced toxicity
MPI: Raikar/Doering
R01AI172452 - 12/2/2022-11/30/2027
Mechano-ID for tagging immune cells
PI: Salaita
Role: Co-I
Previous Funding:
R21CA256605 - 12/10/2020-11/30/2023
Microfluidic platforms to generate 'off-the-shelf' fratricide-resistant CAR T cells for T-cell malignancies
MPI: Raikar/Sulchek
Alexis and Jerry Bednyak Foundation Award for Research in High-Risk Leukemia - Children’s Oncology Group - 3/1/2022-2/28/2023
Leveraging power of multi-dimensional single cell profiling for deep characterization of MPAL
MPI: Raikar/M. Bhasin
CURE Childhood Cancer Foundation - 7/1/2022-6/30/2023
Optimizing gamma delta T-cell immunotherapy for acute myeloid leukemia
Role: PI